Expansion of the Medicare drug price negotiation rare disease drug carve-out would unnecessarily limit the number of drugs ...

US insurance giant Cigna has taken fresh legal action against Bristol Myers Squibb (NYSE: BMY), accusing the drugmaker of ...

Surbhi Sidana, MD, discusses updates from the CARTITUDE-4 study assessing the CAR T therapy cilta-cel in patients with ...

Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse ...

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...

Cigna (NYSE:CI) on Tuesday filed an antitrust lawsuit accusing Bristol Myers Squibb (NYSE:BMY) of breaching U.S. competition ...

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...

During a live event, Binod Dhakal, MD, and participants discussed their experience using selinexor in the second line and ...

BUFFALO, NY - January 23, 2025 – A new editorial was published in Oncoscience’s Volume 12 on January 14, 2025, titled “Pomalidomide improved immune profiles in myeloma." ...

A new editorial was published in Oncoscience's Volume 12 on January 14, 2025, titled "Pomalidomide improved immune profiles in myeloma.". The editorial by researchers Hannah Seah, Vaishnavi Reddy ...

Significant reduction seen in epistaxis severity with pomalidomide treatment for patients with HHT. HealthDay News — For patients with hereditary hemorrhagic telangiectasia (HHT), pomalidomide ...

Pomalidomide, a cancer medication, has been revealed in a clinical trial to be safe and efficacious in treating hereditary hemorrhagic telangiectasia (HHT).This rare bleeding disorder affects more ...